Premium
Ethical Considerations in CYP2D6 Genotype Testing for Codeine‐Prescribed Breastfeeding Mothers
Author(s) -
Kurtz M,
Black Golde P,
Berlinger N
Publication year - 2010
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2010.225
Subject(s) - breastfeeding , codeine , genetic testing , cyp2d6 , genotype , test (biology) , medicine , family medicine , opioid , psychology , pharmacology , pediatrics , genetics , biology , morphine , paleontology , receptor , gene
In this issue, Madadi et al . report on interviews with codeine‐prescribed breastfeeding mothers concerning preferences and attitudes toward receiving their CYP2D6 genotype and overall study findings. We address three sets of ethics questions raised by this article. Should genetic information be disclosed to research participants in genetic research? What should clinicians take into account when considering this genetic test in managing infant opioid toxicity risk? What conditions support or hinder the integration of genetic information into patient care? Clinical Pharmacology & Therapeutics (2010) 88 6, 760–762. doi: 10.1038/clpt.2010.225